Brief: Context Therapeutics' Clinical Partner Stemline Therapeutics Receives FDA Approval Of Orserdu
31/01/2023 13:40
Jan 31 (Reuters) - Context Therapeutics Inc CNTX.O :
* CONTEXT THERAPEUTICS’ CLINICAL PARTNER STEMLINE
THERAPEUTICS, A
SUBSIDIARY OF MENARINI GROUP RECEIVES FDA APPROVAL OF ORSERDU™
(ELACESTRANT) IN ER+, HER2-, ESR1-MUTATED BREAST CANCER
* CONTEXT THERAPEUTICS - ORSERDU IS BEING EVALUATED IN
COMBINATION
WITH CONTEXT'S ONA-XR IN ONGOING ELONA TRIAL
Source text for Eikon: ID:nGNXb5vRy1
Further company coverage: CNTX.O
((reuters.briefs@thomsonreuters.com;))
Recent news on Context Therapeutics
See all newsContext Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Context Therapeutics Q2 net loss widens on higher R&D costs
Context Therapeutics Inc expected to post a loss of 9 cents a share - Earnings Preview
Brief: Context Therapeutics Announces Positive Interim Efficacy And Safety Results From Ongoing Phase 1 Clinical Trial For CTIM-76
Brief: Context Therapeutics Enters Into License Agreement Amendment With BioAtla For CT-202